Existing Funding Sources in Degenerative Cervical Myelopathy Research: Scoping Review.
cervical cord
degeneration
disc herniation
myelopathy
ossification posterior longitudinal ligament
patient and public involvement
research funding
spinal cord
spondylosis
stenosis
systematic review
Journal
Interactive journal of medical research
ISSN: 1929-073X
Titre abrégé: Interact J Med Res
Pays: Canada
ID NLM: 101598421
Informations de publication
Date de publication:
30 Jun 2022
30 Jun 2022
Historique:
received:
05
01
2022
accepted:
17
05
2022
revised:
29
04
2022
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
1
7
2022
Statut:
epublish
Résumé
Degenerative cervical myelopathy (DCM) is a common, disabling condition of symptomatic cervical spinal cord compression that requires significant research advances to improve patient outcomes. A James Lind Alliance Partnership recently identified the top research priorities for DCM. To effectively address these priorities, appropriate funding of DCM research is essential. The aim of this paper is to review current funding in DCM research and highlight future research funding opportunities. A systematic search of Web of Science for "cervical AND myelopathy" was conducted. Papers exclusively studying DCM with declared funding and published between January 1, 1995, and March 21, 2020, were considered eligible. Funding sources were classified by country of origin and organization type. A grant search was also conducted using Dimensions.ai (Digital Science Ltd). A total of 621 papers were included, with 300 unique funding bodies. The top funders were AO Spine (n=87); National Institutes of Health, USA (n=63); and National Natural Science Foundation, China (n=63). Funding sources in the USA (n=242) supported the most DCM research, followed by China (n=209) and Japan (n=116). Funding in the USA was primarily provided by corporate or nonprofit organizations (146/242, 60.3%), while in China, the majority of funding was from institutions (208/209, 99.5%). Dimensions.ai gives an estimate for the total declared grant funding awards for DCM-specific research. Data here showed 180 grants awarded specifically for DCM research, with a total value of US $45.6 million since 1996. DCM funding appears to be predominantly from the USA, China, and Japan, aligning with areas of high DCM research activity and underpinning the importance of funding to increasing research capacity. The existing funding sources differ from medical research in general, representing opportunities for future investment in DCM.
Sections du résumé
BACKGROUND
BACKGROUND
Degenerative cervical myelopathy (DCM) is a common, disabling condition of symptomatic cervical spinal cord compression that requires significant research advances to improve patient outcomes. A James Lind Alliance Partnership recently identified the top research priorities for DCM. To effectively address these priorities, appropriate funding of DCM research is essential.
OBJECTIVE
OBJECTIVE
The aim of this paper is to review current funding in DCM research and highlight future research funding opportunities.
METHODS
METHODS
A systematic search of Web of Science for "cervical AND myelopathy" was conducted. Papers exclusively studying DCM with declared funding and published between January 1, 1995, and March 21, 2020, were considered eligible. Funding sources were classified by country of origin and organization type. A grant search was also conducted using Dimensions.ai (Digital Science Ltd).
RESULTS
RESULTS
A total of 621 papers were included, with 300 unique funding bodies. The top funders were AO Spine (n=87); National Institutes of Health, USA (n=63); and National Natural Science Foundation, China (n=63). Funding sources in the USA (n=242) supported the most DCM research, followed by China (n=209) and Japan (n=116). Funding in the USA was primarily provided by corporate or nonprofit organizations (146/242, 60.3%), while in China, the majority of funding was from institutions (208/209, 99.5%). Dimensions.ai gives an estimate for the total declared grant funding awards for DCM-specific research. Data here showed 180 grants awarded specifically for DCM research, with a total value of US $45.6 million since 1996.
CONCLUSIONS
CONCLUSIONS
DCM funding appears to be predominantly from the USA, China, and Japan, aligning with areas of high DCM research activity and underpinning the importance of funding to increasing research capacity. The existing funding sources differ from medical research in general, representing opportunities for future investment in DCM.
Identifiants
pubmed: 35771617
pii: v11i1e36194
doi: 10.2196/36194
pmc: PMC9284365
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e36194Informations de copyright
©Henry Bestwick, Jye Quan Teh, Oliver Mowforth, Ben Grodzinski, Mark Kotter, Benjamin Davies. Originally published in the Interactive Journal of Medical Research (https://www.i-jmr.org/), 30.06.2022.
Références
Diabet Med. 2017 Oct;34(10):1354-1360
pubmed: 28636762
Lancet. 2014 Jan 18;383(9913):257-66
pubmed: 24411650
Lancet. 2013 Oct 12;382(9900):1286-307
pubmed: 23697824
PLoS One. 2011 Feb 24;6(2):e16837
pubmed: 21383981
Global Spine J. 2020 Dec;10(8):1078-1079
pubmed: 33148026
J Spine Surg. 2020 Mar;6(1):340-350
pubmed: 32309671
J Neurosurg Spine. 2020 Jan 3;:1-3
pubmed: 31899877
Spine (Phila Pa 1976). 2016 Dec 15;41(24):1908-1916
pubmed: 27509189
Acta Neurochir (Wien). 2021 Jun;163(6):1561-1568
pubmed: 33625603
Neuroscientist. 2013 Aug;19(4):409-21
pubmed: 23204243
Lancet. 2014 Jan 11;383(9912):156-65
pubmed: 24411644
Spine (Phila Pa 1976). 2015 Jun 15;40(12):E675-93
pubmed: 25839387
World Neurosurg. 2017 Oct;106:699-706
pubmed: 28065875
JMIR Res Protoc. 2020 Jun 11;9(6):e15922
pubmed: 32525490
Global Spine J. 2017 Sep;7(3 Suppl):70S-83S
pubmed: 29164035
Glob Health Action. 2010 Apr 06;3:
pubmed: 20386617
Lancet. 2014 Jan 4;383(9911):94-97
pubmed: 24388312
Lancet Glob Health. 2017 Jan;5(1):e25-e27
pubmed: 27955774
Global Spine J. 2021 May;11(4):597-607
pubmed: 32677521
BMJ. 2018 Feb 22;360:k186
pubmed: 29472200
Health Res Policy Syst. 2017 Mar 21;15(1):24
pubmed: 28327164
Lancet. 2014 Jan 11;383(9912):166-75
pubmed: 24411645
J Transl Med. 2019 May 10;17(1):150
pubmed: 31077194
Global Spine J. 2021 Jul;11(6):988-998
pubmed: 32869687
Health Res Policy Syst. 2016 Feb 18;14:12
pubmed: 26892771
Nat Rev Neurol. 2020 Feb;16(2):108-124
pubmed: 31974455
Eur J Cancer. 2018 Sep;100:75-84
pubmed: 30014883
Global Spine J. 2020 Jun;10(4):476-485
pubmed: 32435569
PLoS One. 2017 Mar 1;12(3):e0172564
pubmed: 28249017
Metab Brain Dis. 2014 Jun;29(2):217-20
pubmed: 24166356
Global Spine J. 2019 May;9(1 Suppl):65S-76S
pubmed: 31157148
Spine (Phila Pa 1976). 2020 Oct 1;45(19):E1286-E1287
pubmed: 32925823
BMC Med Res Methodol. 2018 Jul 6;18(1):73
pubmed: 29976134
J Rheumatol. 2020 Apr;47(4):633-634
pubmed: 32062608
PLoS One. 2016 Aug 02;11(8):e0157263
pubmed: 27482710